Erythromycin Panpharma Powder for solution for Infusion
Erythromycin
1000mg
PANPHARMA
| Pack size | 10 Glass Vials |
|---|---|
| Dispensing mode | POM |
| Source | FRANCE |
| Agent | PHARMALINK |
| Retail Price | 837.00 AED |
Available as:
Indications
Erythromycin Panpharma Powder for solution for Infusion is used for:
Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.
Adult Dose
Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection.
Upper respiratory tract infections of mild to moderate severity: 250 to 500 mg 4 times a day for 10 days.
Lower respiratory infections of mild to moderate severity: 250 to 500 mg 4 times a day for 10 days.
Respiratory tract infections due to Mycoplasma pneumoniae: 500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks.
Skin and soft tissue infections of mild to moderate severity: 250 to 500 mg 4 times a day for 10 days.
Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae: 500 mg 4 times a day for 10 to 14 days.
Urogenital infection during pregnancy caused by Chlamydia trachomatis: 500 mg 4 times daily for 7 days or
250 mg 4 times daily for 14 days.
Urethral, endocervical or rectal infections, uncomplicated: 500 mg 4 times daily for 7 days or
250 mg 4 times daily for 14 days.
Non-gonococcal urethritis: 500 mg 4 times daily for at least 7 days.
Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG): 500 mg 4 times a day for 7 days.
Early syphillis (primary, secondary or latent syphillis of < 1 year duration): 500 mg 4 times a day for 14 days.
Severe or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever: 250 mg 2 times daily.
Bacterial endocarditis: 1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose.
Acne: 500 mg twice daily for 3 months reduced to 250 mg twice for 3 months.
Hepatic Impairment
Use caution
Child Dose
Children:
PO 50 mg/kg/day q6–8h
Renal Dose
Renal Impairment
Dose adjustment not necessary
Administration
Should be taken on an empty stomach. Best taken on an empty stomach at least ½ hr & preferably 2 hr before meals.
Reconstitution: Oral susp: Add 77 mL of water and shake vigorously. This makes 100 mL susp.
Contra Indications
Hypersensitivity; porphyria; hepatic impairment; pregnancy.
Precautions
Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
Lactation: distributed in breast milk, use with caution; AAP categorizes as compatible with breastfeeding
Pregnancy-Lactation
Pregnancy category: B
Lactation: Drug enters breast milk; use with caution (American Academy of Pediatrics committee states that drug is compatible with nursing)
Interactions
May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
Adverse Effects
Side effects of Erythromycin :
1-10%
Abdominal pain (8%), Headache (8%), Nausea (8%), Diarrhea (7%), Rash (3%), Vomiting (3%), Dyspepsia (2%), Flatulence (2%), Pain (2%), Pruritus (1%), Pseudomembranous colitis
Hypertrophic pyloric stenosis, Anaphylaxis, Fever, Mild allergic reactions, Urticaria, Skin eruptions, Tinnitus
<1%
Cholestatic hepatitis, Confusion, Hallucinations, Hearing loss, Hypotension, Nervous system effects including seizures, Torsade de pointes, Ventricular tachycardia, Vertigo
Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
Mechanism of Action
Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
Note
Erythromycin Panpharma 1000mg Powder for solution for Infusion manufactured by PANPHARMA. Its generic name is Erythromycin. Erythromycin Panpharma is availble in United Arab Emirates.
Farmaco UAE drug index information on Erythromycin Panpharma Powder for solution for Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Erythromycin :
Drops (Oral)
Rythinate
40mg/ml
Al Hikma Pharmaceuticals
Suspension
Rythinate
200mg/5ml
Al Hikma Pharmaceuticals
Suspension
Omathrocin
200mg/5ml
National Pharmaceutical industries Co. (SAOG)
Tablets / Film-coated
Omathrocin
250mg
National Pharmaceutical industries Co. (SAOG)
Drops (Oral)
Omathrocin
40mg/ml
National Pharmaceutical industries Co. (SAOG)